Writing in the Journal of the American Medical Association, a group of leading cardiologists and other doctors warned of serious health risks associated with the diabetes drug Pargluva, including an elevated risk of heart attacks and a possible link to cancer. Pargluva is not yet on the market but has been recommended for approval by an FDA committee and is expected to be a blockbuster. The editorial, which is authored by McGill University's Dr. James M. Brophy, is particularly critical of the methodology which Bristol-Myers Squibb and Merck used to gather safety data on the drug, suggesting that many of the people who would be given the drug in real life were excluded from the data.
- see this article from The New York Times